Sanofi, Mass General collaborate on cancer drug research; GSK teams with Aeras on TB vaccine;

Conversations on Twitter :

 @FierceBiotech: Diamyd Medical sells off nerve-targeted delivery unit. More | Follow @FierceBiotech

 @JohnCFierce: I'd like to see Lilly file an NDA on sola, see how regulators handle secondary analysis on data from 1 trial that couldn't be confirmed in 2nd. | Follow @JohnCFierce

 @RyanMFierce: Top counterfeit drug events in 2012 report, shows this problem affects all of us. More | Follow @RyanMFierce

> Sanofi ($SNY) will collaborate with the Massachusetts General Hospital on a two-year translational medicine pact covering the development of new cancer drugs. Scientists from both will be spearheading efforts to obtain proof-of-concept data on drugs. Sanofi has been steadily building up its R&D presence in Boston. Release

> GlaxoSmithKline ($GSK) says it will team up with the nonprofit Aeras group to test an experimental TB vaccine. Story

> QRxPharma has executed a pact with Paladin Labs for the Canadian commercialization rights to MOXDUO, an immediate release formulation of morphine and oxycodone. Release

Pharma News

@FiercePharma: Will Optimer's plan to boost Dificid sales work? It's a volume-pricing move. More | Follow @FiercePharma

> Teva's 2nd-gen Copaxone makes the grade. Report

> No breakup for J&J? Goldman analyst says 'Sell'. Story

> Pfizer wraps up Celebrex suit in $164M settlement. News

> Should new drugs wear 'proceed with caution' labels? Article

Medical Device News

 @FierceMedDev: Check out our rundown of the year's biggest announced layoffs in the medical device world. More | Follow @FierceMedDev

 @MarkHFierce: BD's CFO is leaving to pursue an "entrepreneurial opportunity." More | Follow @MarkHFierce

 @DamianFierce: Biomet reduced its quarterly losses thanks to its $280M buy of DePuy's trauma unit. More | Follow @DamianFierce

> Hospital transparency may be driving down stent use. Report

> Researchers: Concealing a stent with antibodies will prevent clots. Story

> Study: FDA, CMS device approval times still run long. Item

Drug Delivery News

> NuPathe axes half its workforce, sells $28M of securities. Article

> Dissolving microneedles hit the sweet spot in diabetes. Item

> Diamyd Medical sells off nerve-targeted delivery unit. Story

> Smaller electric pulse hits the spot for DNA vaccines. Report

Biomarkers News

> Scratching a genetic itch in atopic dermatitis. More

> Biomarker panel spots the risk of Type 2 diabetes. Report

> Making a GENIE-us connection: Linking genes with diabetic kidney disease. Story

> Prostate cancer genetic barcodes predict aggressiveness. Article

And Finally… Investigators at the University of Illinois say they think they know why coffee has been linked to a reduction in risk for Alzheimer's, suggesting that the caffeine may be blocking inflammation that causes cognitive problems. Story


Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.